{"id":843034,"date":"2025-04-28T18:58:07","date_gmt":"2025-04-28T22:58:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/"},"modified":"2025-04-28T18:58:07","modified_gmt":"2025-04-28T22:58:07","slug":"heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/","title":{"rendered":"Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">CARY, N.C.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">April 28, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Heron Therapeutics, Inc. (Nasdaq: HRTX) (&#8220;Heron&#8221; or the &#8220;Company&#8221;), a commercial-stage biotechnology company, today announced the appointment of\u00a0Mark Hensley\u00a0as Chief Operating Officer.\u00a0Mr. Hensley\u00a0has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry.<\/p>\n<p>&#8220;I am excited to welcome Mark to Heron as our new Chief Operating Officer,&#8221; said <span class=\"xn-person\">Craig Collard<\/span>, Chief Executive Officer of Heron. &#8220;Mark brings extensive operational and leadership experience that positions him to play a pivotal role in our next phase of growth. His experience will be instrumental in ensuring we operate with efficiency, effectiveness, and compliance as we advance our strategic priorities and execute on our growth initiatives.&#8221;<\/p>\n<p>Mr. Hensley\u00a0brings extensive leadership and operational experience to Heron. Prior to joining Heron,\u00a0Mr. Hensley\u00a0held several senior leadership roles at\u00a0Veloxis Pharmaceuticals, Inc. (&#8220;Veloxis&#8221;), a fully integrated specialty pharmaceutical company, including serving as Chief Executive Officer from 2021 to 2024, and Chief Operating Officer and Chief Commercial Officer from 2018 to 2021. Earlier in his career, Mr. Hensley held positions of increasing responsibility at Cornerstone Therapeutics and Chiesi <span class=\"xn-location\">USA<\/span>. Mr. Hensley holds a Bachelor of Science in Biology and a Minor in Chemistry from the <span class=\"xn-org\">University of North Texas<\/span>.<\/p>\n<p>In connection with the commencement of\u00a0Mr. Hensley&#8217;s\u00a0employment, Mr. Hensley\u00a0will receive inducement awards consisting of (i) a non-statutory stock option to purchase 500,000 shares of Heron common stock (&#8220;Inducement Option&#8221;), (ii) 500,000 restricted stock units (&#8220;Inducement RSUs&#8221;), and (iii) a non-statutory stock option to purchase up to 900,000 shares of Heron common stock based upon the achievement of certain common stock price goals (&#8220;Inducement PSO&#8221;). The Inducement Option and Inducement PSO each have an exercise price based on the closing price per share as reported on the Nasdaq Capital Market as of\u00a0April 28, 2025, the effective date of the grants and the start date of\u00a0Mr. Hensley&#8217;s\u00a0employment with Heron. The Inducement Option has a 10-year term with a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the grant date and the remaining 75% vesting on a monthly basis over the next three years, subject to\u00a0Mr. Hensley&#8217;s\u00a0continuous service through each vesting date. The Inducement RSUs vest as to 25% of the shares subject to the Inducement RSUs on each of the first four anniversaries of the grant date, subject to\u00a0Mr. Hensley&#8217;s\u00a0continuous service through each such vesting date. The Inducement PSO has a 10-year term and vests as to a certain number of shares of the Company&#8217;s common stock upon achievement of certain stock price goals during\u00a0Mr. Hensley&#8217;s\u00a0employment with the Company and during the term of the Inducement PSO, subject to\u00a0Mr. Hensley&#8217;s\u00a0continuous service through each such vesting date. In accordance with Nasdaq Listing Rule 5635(c)(4), the inducement award grants were approved by the Compensation Committee of the Board of Directors and were made as a material inducement to\u00a0Mr. Hensley entering into employment with Heron.<\/p>\n<p>\n        <b>About\u00a0Heron Therapeutics, Inc.<\/b>\n      <\/p>\n<p>Heron Therapeutics, Inc.\u00a0is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4415306-1&amp;h=1778672907&amp;u=http%3A%2F%2Fwww.herontx.com%2F&amp;a=www.herontx.com\" target=\"_blank\" rel=\"nofollow\">www.herontx.com<\/a>.<\/p>\n<p>\n        <b>Forward-looking Statements<\/b>\n      <\/p>\n<p>This news release contains &#8220;forward-looking statements&#8221; as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management&#8217;s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Therefore, you should not place undue reliance on forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the\u00a0Securities and Exchange Commission, including under the caption &#8220;Risk Factors.&#8221; Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.<\/p>\n<p>\n        <b>Investor Relations and Media Contact:<\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Ira Duarte<\/span><br \/>\n        <br \/>Executive Vice President, Chief Financial Officer<br \/>Heron Therapeutics, Inc.<br \/><a href=\"mailto:iduarte@herontx.com\" target=\"_blank\" rel=\"nofollow\">iduarte@herontx.com<\/a><br \/>858-251-4400<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1482\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1874825\/Heron_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1874825\/Heron_Logo.jpg\" title=\"(PRNewsfoto\/Heron Therapeutics, Inc.)\" alt=\"(PRNewsfoto\/Heron Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA75117&amp;sd=2025-04-28\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer-302440350.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer-302440350.html<\/a><\/p>\n<p>SOURCE  Heron Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA75117&amp;Transmission_Id=202504281855PR_NEWS_USPR_____LA75117&amp;DateId=20250428\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire CARY, N.C. , April 28, 2025 \/PRNewswire\/ &#8212; Heron Therapeutics, Inc. (Nasdaq: HRTX) (&#8220;Heron&#8221; or the &#8220;Company&#8221;), a commercial-stage biotechnology company, today announced the appointment of\u00a0Mark Hensley\u00a0as Chief Operating Officer.\u00a0Mr. Hensley\u00a0has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry. &#8220;I am excited to welcome Mark to Heron as our new Chief Operating Officer,&#8221; said Craig Collard, Chief Executive Officer of Heron. &#8220;Mark brings extensive operational and leadership experience that positions him to play a pivotal role in our next phase of growth. His experience will be instrumental in ensuring we operate with efficiency, effectiveness, and compliance as we advance our strategic priorities and execute on our growth initiatives.&#8221; &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-843034","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire CARY, N.C. , April 28, 2025 \/PRNewswire\/ &#8212; Heron Therapeutics, Inc. (Nasdaq: HRTX) (&#8220;Heron&#8221; or the &#8220;Company&#8221;), a commercial-stage biotechnology company, today announced the appointment of\u00a0Mark Hensley\u00a0as Chief Operating Officer.\u00a0Mr. Hensley\u00a0has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry. &#8220;I am excited to welcome Mark to Heron as our new Chief Operating Officer,&#8221; said Craig Collard, Chief Executive Officer of Heron. &#8220;Mark brings extensive operational and leadership experience that positions him to play a pivotal role in our next phase of growth. His experience will be instrumental in ensuring we operate with efficiency, effectiveness, and compliance as we advance our strategic priorities and execute on our growth initiatives.&#8221; &hellip; Continue reading &quot;Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-28T22:58:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1874825\/Heron_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer\",\"datePublished\":\"2025-04-28T22:58:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\\\/\"},\"wordCount\":763,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1874825\\\/Heron_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\\\/\",\"name\":\"Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1874825\\\/Heron_Logo.jpg\",\"datePublished\":\"2025-04-28T22:58:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1874825\\\/Heron_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1874825\\\/Heron_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/","og_locale":"en_US","og_type":"article","og_title":"Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer - Market Newsdesk","og_description":"PR Newswire CARY, N.C. , April 28, 2025 \/PRNewswire\/ &#8212; Heron Therapeutics, Inc. (Nasdaq: HRTX) (&#8220;Heron&#8221; or the &#8220;Company&#8221;), a commercial-stage biotechnology company, today announced the appointment of\u00a0Mark Hensley\u00a0as Chief Operating Officer.\u00a0Mr. Hensley\u00a0has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry. &#8220;I am excited to welcome Mark to Heron as our new Chief Operating Officer,&#8221; said Craig Collard, Chief Executive Officer of Heron. &#8220;Mark brings extensive operational and leadership experience that positions him to play a pivotal role in our next phase of growth. His experience will be instrumental in ensuring we operate with efficiency, effectiveness, and compliance as we advance our strategic priorities and execute on our growth initiatives.&#8221; &hellip; Continue reading \"Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-28T22:58:07+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1874825\/Heron_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer","datePublished":"2025-04-28T22:58:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/"},"wordCount":763,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1874825\/Heron_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/","name":"Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1874825\/Heron_Logo.jpg","datePublished":"2025-04-28T22:58:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1874825\/Heron_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1874825\/Heron_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-mark-hensley-as-chief-operating-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/843034","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=843034"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/843034\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=843034"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=843034"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=843034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}